A Continuation Study of Herceptin (Trastuzumab) in Participants With Metastatic or Locally Advanced Cancer
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
This study is designed to provide continued access to intravenous (IV) Herceptin and to
evaluate long-term outcomes and overall safety in participants with stable disease and human
epidermal growth factor 2 (HER2)-overexpressing metastatic or locally advanced cancer who
have completed a prior study with IV Herceptin.